The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function
Tóm tắt
Vascular endothelial dysfunction is a complex phenomenon that is caused by an imbalance of vasodilator and vasoconstrictor factors that regulate the equilibrium-maintaining vascular tone. In the early phase of hypercholesterolemia, endothelial dysfunction precedes vascular wall lesions. One of the earliest recognizable benefits of treatment with HMG-CoA reductase inhibitors (statins) is the normalization of endothelium-dependent relaxation in hypercholesterolemia; this effect occurs before significant lowering of serum cholesterol levels. Recent insights into cellular mechanisms indicate that statins promote vasorelaxation by upregulating the expression of endothelial nitric oxide (NO) synthase, activating the phosphatidylinositide 3-kinase/Akt pathway, inhibiting Superoxide anion generation and endothelin synthesis, and by anti-inflammatory effects. These effects appear to be linked to the inhibition of geranylgeranylation of small G proteins such as Rho and Rac GTPases. In this regard, statins preserve endothelial function through the improvement of NO bioavailability and the reduction of oxidative stress, thereby shifting the balance from vasoconstriction to vasodilation. This review highlights the various mechanisms underlying the vasculoprotective effects of statins, independent of their effects on cholesterol lowering.
Tài liệu tham khảo
Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425–30.
Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221–5.
Clarke S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 1992; 61: 355–86.
Clunn GF, Lymn JS, Schachter M, et al. Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells. Br J Pharmacol 1997; 121: 1789–95.
Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin, simvastatin and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999; 34: 95–101.
Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109–41.
Bogey RH, Bode-Boger SM, Frolich JC. The L-arginine nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127: 1–11.
Casino PR, Kilcoyne CM, Cannon III RO, et al. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor. Am J Cardiol 1995; 75: 40–4.
Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496–500.
Reddy KG, Nair R, Sheehan HM, et al. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23: 833–43.
Ohara Y, Ptereson TE, Harrison DG. Hypercholesterolemia increases endothelial Superoxide anion production. J Clin Invest 1993; 91: 2546–51.
Treasure CB, Klein L, Weintraub WS, et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481–7.
O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–31.
Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis investigation program. Circulation 1995; 92: 2419–25.
Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348(9034): 1079–82.
Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684–91.
Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111(18): 2356–63.
John S, Schneider MP, Delies C, et al. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149(3): 473.
Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000; 102(8): 846–51.
Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129–35.
Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711–9.
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118.
Brandes RP. Statin-mediated inhibition of Rho: only to get more NO? Circ Res 2005; 96(9): 927–9.
Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6(9): 1004–10.
Gratton JP, Bernatchez P, Sessa WC. Caveolae and caveolins in the cardiovascular system. Circ Res 2004; 94(11): 1408–17.
Okamoto T, Schlegel A, Scherer PE, et al. Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. J Biol Chem 1998; 273(10): 5419–22.
Ju H. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 1997; 272(30): 18522–5.
Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl cooenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113–8.
McDonald KK, Zharikov S, Block ER, et al. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric oxide synthase may explain the arginine paradox. J Biol Chem 1997; 272: 31213–6.
Parker RA, Huang Q, Tesfamariam B. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 2003; 169(1): 19–29.
Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154(1): 87–96.
Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450–7.
Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial Superoxide anion formation. Arterioscl Thromb Vasc Biol 2000; 20: 61–9.
Flowers MA, Wang Y, Stewart RJ, et al. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol 1995; 269(6): H1988–97.
Kimura M, Kurose I, Russel J, et al. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997; 17: 1521–6.
Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholestrolemic patients; role of nitric oxide. J Invest Med 2000; 48: 183–9.
Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111(4): 412–9.
Albert MA, Staggers J, Chew P, et al. PRINCE Investigators. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 2001; 141(6): 893–8.
Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439–41.
Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105(15): 1756–9.
Masamura K, Oida K, Kanehara H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003; 23(3): 512–7.
Bourcier T, Libby P. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556–62.
Bickel C, Rupprecht HJ, Blankenberg S, et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002; 82(1): 25–31.
Vasa M, Fichtischerer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103(24): 2885–90.
Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow: derived endothelial progenitor cells. J Clin Invest 2001; 108(3): 399–405.
Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105(25): 3017–24.
Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105(6): 739–45.
Urbich C, Dernbach E, Zeiher AM, et al. Double-edged role of statins in angiogenesis signaling. Circ Res 2002; 90(6): 737–44.
Sata M, Nishimatsu H, Suzuki E, et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J 2001; 15(13): 2530–2.